These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 27904082)
21. Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA. Wu J; Zhu H; Yang G; He J; Wang Y; Zhao S; Zhang X; Gui L; Zhao M; Peng S Int J Nanomedicine; 2018; 13():1139-1158. PubMed ID: 29520141 [TBL] [Abstract][Full Text] [Related]
22. Chemical synthesis and structural characterization of the RGD-protein decorsin: a potent inhibitor of platelet aggregation. Polverino de Laureto P; Scaramella E; De Filippis V; Marin O; Doni MG; Fontana A Protein Sci; 1998 Feb; 7(2):433-44. PubMed ID: 9521121 [TBL] [Abstract][Full Text] [Related]
23. Low molecular weight, non-peptide fibrinogen receptor antagonists. Alig L; Edenhofer A; Hadváry P; Hürzeler M; Knopp D; Müller M; Steiner B; Trzeciak A; Weller T J Med Chem; 1992 Nov; 35(23):4393-407. PubMed ID: 1447740 [TBL] [Abstract][Full Text] [Related]
24. New platelet aggregation inhibitors based on pyridazinone moiety. Costas T; Costas-Lago MC; Vila N; Besada P; Cano E; Terán C Eur J Med Chem; 2015 Apr; 94():113-22. PubMed ID: 25757094 [TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationships of chalcone analogs as potential inhibitors of ADP- and collagen-induced platelet aggregation. Vijaya Bhaskar Reddy M; Tsai WJ; Qian K; Lee KH; Wu TS Bioorg Med Chem; 2011 Dec; 19(24):7711-9. PubMed ID: 22055718 [TBL] [Abstract][Full Text] [Related]
27. The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action. Yang G; Zhu H; Zhao M; Wu J; Wang Y; Wang Y; Zheng M; Chen M; Liu J; Peng S Mol Biosyst; 2012 Oct; 8(10):2672-9. PubMed ID: 22801714 [TBL] [Abstract][Full Text] [Related]
28. A shortcut to peptides to modulate platelets. Apic G; Russell RB Nat Chem Biol; 2007 Feb; 3(2):83-4. PubMed ID: 17235341 [No Abstract] [Full Text] [Related]
29. Evaluation of arginine-glycine-aspartate-containing peptides as inhibitors of equine platelet function. Weiss DJ; Evanson OA; Wells RE Am J Vet Res; 1997 May; 58(5):457-60. PubMed ID: 9140550 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and antiaggregatory activity of RGD-peptidomimetics based on 4-oxo-4-(piperazine-1-yl)butyric acid as Arg-mimetic. Andronati SA; Krysko AA; Kabanov VM; Kabanova TA; Karaseva TL; Chugunov BM; Meshkova SB; Topilova ZM Acta Pol Pharm; 2003; 60(5):375-81. PubMed ID: 15005421 [TBL] [Abstract][Full Text] [Related]
31. Synthesis of RGD analogs as potential vectors for targeted drug delivery. Jiang J; Wang W; Sane DC; Wang B Bioorg Chem; 2001 Dec; 29(6):357-79. PubMed ID: 11846434 [TBL] [Abstract][Full Text] [Related]
32. Three-dimensional quantitative structure-activity relationship analyses of RGD mimetics as fibrinogen receptor antagonists. Miyashita M; Akamatsu M; Hayashi Y; Ueno T Bioorg Med Chem Lett; 2000 May; 10(9):859-63. PubMed ID: 10853647 [TBL] [Abstract][Full Text] [Related]
33. New 1H-pyrazole-4-carboxamides with antiplatelet activity. Rehse K; Kotthaus J; Khadembashi L Arch Pharm (Weinheim); 2009 Jan; 342(1):27-33. PubMed ID: 19051198 [TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities. Alexopoulos K; Fatseas P; Melissari E; Vlahakos D; Roumelioti P; Mavromoustakos T; Mihailescu S; Paredes-Carbajal MC; Mascher D; Matsoukas J J Med Chem; 2004 Jun; 47(13):3338-52. PubMed ID: 15189031 [TBL] [Abstract][Full Text] [Related]
35. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities. Chen H; Mo W; Su H; Zhang Y; Song H BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340 [TBL] [Abstract][Full Text] [Related]
36. Synthesis and anti-platelet activity of obovatol derivatives. Kwak JH; Lee S; Park ES; In JK; Song J; Kim YJ; Choi NS; Lee H; Yun YP; Hong JT; Kwak YS; Min KH; Jung JK Arch Pharm Res; 2011 Jul; 34(7):1107-12. PubMed ID: 21811917 [TBL] [Abstract][Full Text] [Related]
37. Synthesis and anti-platelet evaluation of 2-benzoylaminobenzoate analogs. Hsieh PW; Chiang SZ; Wu CC; Lo YC; Shih YT; Wu YC Bioorg Med Chem; 2008 May; 16(10):5803-14. PubMed ID: 18407506 [TBL] [Abstract][Full Text] [Related]
38. Derivatives of tetrahydroisoquinoline: synthesis and initial evaluation of novel non-peptide antagonists of the alpha(IIb)beta(3)-integrin. Krysko AA; Krysko OL; Kabanova TA; Andronati SA; Kabanov VM Bioorg Med Chem Lett; 2010 Aug; 20(15):4444-6. PubMed ID: 20598885 [TBL] [Abstract][Full Text] [Related]
39. [A new thrombocyte aggregation-inhibiting and fibrinolysis-promoting synthetic molecule: RGDF (Arg-Gly-Asp-Phe) coupled with the carboxyterminal antiplasmin peptide]. Udrardy M; Schwartzott D; Jackson K; McKee PA Orv Hetil; 1995 Jan; 136(3):129-33. PubMed ID: 7870410 [TBL] [Abstract][Full Text] [Related]
40. Hybrid peptide containing RGDF (Arg-Gly-Asp-Phe) coupled with the carboxy terminal part of alpha 2-antiplasmin capable of inhibiting platelet aggregation and promoting fibrinolysis. Udvardy M; Schwartzott D; Jackson K; McKee PA Blood Coagul Fibrinolysis; 1995 Feb; 6(1):11-6. PubMed ID: 7795148 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]